Denali Therapeutics Inc. (DNLI) Earnings History
Net Loss11 years of earnings data (2015–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Denali Therapeutics Inc. (DNLI) Earnings Overview
As of June 22, 2026, Denali Therapeutics Inc. (DNLI) reported trailing twelve-month net income of -$508M, reflecting -15.6% year-over-year growth. The company earned $-2.72 per diluted share over the past four quarters.
Looking at the long-term picture, DNLI's historical earnings data spans multiple years. The company achieved its highest annual net income of $71M in fiscal 2020.
Denali Therapeutics Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including PRAX (-$327M net income), ARVN (-$221M net income, -30.8% margin), RCUS (-$369M net income, -142.9% margin), DNLI has comparable earnings metrics. Compare DNLI vs PRAX →
DNLI Earnings vs Peers
Earnings metrics vs comparable public companies
DNLI Historical Earnings Data (2015–2025)
11 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$513M | -21.2% | -$555M | $-2.97 | - | - |
| 2024 | -$423M | -191.1% | -$487M | $-2.57 | - | - |
| 2023 | -$145M | +55.5% | -$197M | $-1.06 | -43.9% | -59.5% |
| 2022 | -$326M | -12.2% | -$341M | $-2.60 | -300.6% | -314.2% |
| 2021 | -$291M | -508.5% | -$296M | $-2.39 | -597.2% | -607.8% |
| 2020 | $71M | +136.0% | $63M | $0.63 | 21.2% | 18.7% |
| 2019 | -$198M | -445.3% | -$213M | $-2.07 | -740.7% | -799.1% |
| 2018 | -$36M | +58.9% | -$46M | $-0.39 | -28.1% | -35.9% |
| 2017 | -$88M | -1.8% | -$90M | $-5.89 | - | - |
| 2016 | -$87M | -416.2% | -$87M | $-13.49 | - | - |
| 2015 | -$17M | - | -$17M | $-5.58 | - | - |
Download Data
Export DNLI earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
11+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
DNLI — Frequently Asked Questions
Quick answers to the most common questions about buying DNLI stock.
What is DNLI earnings per share (EPS)?
DNLI trailing twelve-month (TTM) diluted EPS is $-2.72, reflecting -15.6% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2015 to 2025 is available in the table on this page.
What is Denali Therapeutics Inc.'s net income?
Denali Therapeutics Inc. (DNLI) trailing twelve-month net income is $-508M as of 2025. Earnings declined -15.6% year-over-year.
Is DNLI profitable?
DNLI is not currently profitable on a TTM basis, reporting a net loss of $-508M. Net margin is N/A. Investors should monitor for a return to profitability.
What is DNLI's earnings growth rate?
DNLI compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2015 to 2025.
What are DNLI's profit margins?
Denali Therapeutics Inc. net profit margin is N/A, operating margin is N/A, and gross margin is N/A. Below-average margins reflect competitive or cost pressures. Return on Equity is -45.7%.
Is DNLI growing earnings?
DNLI earnings are declining — EPS fell -15.6% year-over-year. TTM net income dropped to $-508M. This contrasts with the 5-year CAGR of N/A.
What was DNLI's best earnings year?
Denali Therapeutics Inc.'s highest annual net income on record is $71M, achieved in fiscal year 2020. Earnings history on this page spans 2015 to 2025 and includes all annual and quarterly figures.
What were DNLI's earnings last quarter?
DNLI's most recent reported quarter was Q1 2026. Net income was $-128M with diluted EPS of $-0.69. For a full breakdown of all quarters, see the quarterly earnings table on this page.